Filing Flows › Halozyme Therapeutics (HALO) › Free cash flow
Halozyme Therapeutics (HALO) free cash flow by quarter
Halozyme Therapeutics' free cash flow was $255M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $98.1M (Q2 2025) to $255M (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $255M | +8% | +45% |
| Q2 2026 | $237M | +34% | +141% |
| Q1 2026 | $176M | -19% | +15% |
| Q4 2025 | $218M | +24% | — |
| Q3 2025 | $176M | +79% | — |
| Q2 2025 | $98.1M | -36% | — |
| Q1 2025 | $153M | — | — |
Q3 2026 at a glance
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is Halozyme Therapeutics' free cash flow?
Halozyme Therapeutics' free cash flow was $255M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has Halozyme Therapeutics' free cash flow changed?
Over the last 7 quarters it ranged from $98.1M (Q2 2025) to $255M (Q3 2026).